Literature DB >> 24936338

Modeling the time dependent biodistribution of Samarium-153 ethylenediamine tetramethylene phosphonate using compartmental analysis.

Parandoush Abbasian1, Monika Foroghy2, Amir Reza Jalilian3, Amir Hakimi1, Simindokht Shirvani-Arani3.   

Abstract

AIM: The main purpose of this work was to develop a pharmacokinetic model for the bone pain palliation agent Samarium-153 ethylenediamine tetramethylene phosphonate ([(153)Sm]-EDTMP) in normal rats to analyze the behavior of the complex.
BACKGROUND: The use of compartmental analysis allows a mathematical separation of tissues and organs to determine the concentration of activity in each fraction of interest. Biodistribution studies are expensive and difficult to carry out in humans, but such data can be obtained easily in rodents.
MATERIALS AND METHODS: We have developed a physiologically based pharmacokinetic model for scaling up activity concentration in each organ versus time. The mathematical model uses physiological parameters including organ volumes, blood flow rates, and vascular permabilities; the compartments (organs) are connected anatomically. This allows the use of scale-up techniques to predict new complex distribution in humans in each organ.
RESULTS: The concentration of the radiopharmaceutical in various organs was measured at different times. The temporal behavior of biodistribution of (153)Sm-EDTMP was modeled and drawn as a function of time.
CONCLUSIONS: The variation of pharmaceutical concentration in all organs is described with summation of 6-10 exponential terms and it approximates our experimental data with precision better than 2%.

Entities:  

Keywords:  Biodistribution modeling; Compartmental analysis; [153Sm]-EDTMP

Year:  2013        PMID: 24936338      PMCID: PMC4056545          DOI: 10.1016/j.rpor.2013.12.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  12 in total

1.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.

Authors:  J A Siegel; S R Thomas; J B Stubbs; M G Stabin; M T Hays; K F Koral; J S Robertson; R W Howell; B W Wessels; D R Fisher; D A Weber; A B Brill
Journal:  J Nucl Med       Date:  1999-02       Impact factor: 10.057

Review 2.  [153Sm]EDTMP: a potential therapy for bone cancer pain.

Authors:  R A Holmes
Journal:  Semin Nucl Med       Date:  1992-01       Impact factor: 4.446

3.  Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases.

Authors:  M Tripathi; T Singhal; N Chandrasekhar; P Kumar; C Bal; P K Jhulka; G Bandopadhyaya; A Malhotra
Journal:  Indian J Cancer       Date:  2006 Apr-Jun       Impact factor: 1.224

4.  Simulation software for the macintosh.

Authors:  D K Bogen
Journal:  Science       Date:  1989-10-06       Impact factor: 47.728

Review 5.  Radiotherapy for bone pain.

Authors:  P J Hoskin
Journal:  Pain       Date:  1995-11       Impact factor: 6.961

Review 6.  Radionuclide therapy of intractable bone pain: emphasis on strontium-89.

Authors:  R G Robinson; D F Preston; J A Spicer; K G Baxter
Journal:  Semin Nucl Med       Date:  1992-01       Impact factor: 4.446

7.  Samarium-153-EDTMP biodistribution and dosimetry estimation.

Authors:  J F Eary; C Collins; M Stabin; C Vernon; S Petersdorf; M Baker; S Hartnett; S Ferency; S J Addison; F Appelbaum
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

Review 8.  Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?

Authors:  D P Dearnaley; R J Bayly; R P A'Hern; J Gadd; M M Zivanovic; V J Lewington
Journal:  Clin Oncol (R Coll Radiol)       Date:  1992-03       Impact factor: 4.126

9.  Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.

Authors:  W F Goeckeler; B Edwards; W A Volkert; R A Holmes; J Simon; D Wilson
Journal:  J Nucl Med       Date:  1987-04       Impact factor: 10.057

10.  Modeling the time dependent distribution of a new (153)Sm complex for targeted radiotherapy purpose.

Authors:  Dariush Sardari; Amir Hakimi
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.